Dr. Reddy's Recalls Divalproex Sodium Tablets for Dissolution Failure
Dr. Reddy's Laboratories is recalling Divalproex Sodium Extended-Release Tablets because they failed to meet dissolution specifications at the 9-hour time point.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a failure to meet dissolution specifications without reported injuries or illnesses, fitting the criteria for a moderate severity voluntary precautionary recall.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling Divalproex Sodium Extended-Release Tablets, USP, 250 mg and 500 mg. The affected products are prescription-only tablets manufactured in India and distributed nationwide. The recall involves specific lots of 100-count and 500-count bottles with expiration dates of 09/2015.
The recall was initiated because the tablets failed to meet dissolution specifications, specifically exceeding the specification at the 9-hour time point. This indicates that the tablets may not release the medication at the intended rate.
Consumers and healthcare providers should stop using the affected lots and contact their healthcare provider for guidance on alternative treatment. The affected lots are identified as Lot #C307859 and Lot #C307812.
The recalled product
- Product
- DIVALPROEX SODIUM (DIVALPROEX SODIUM)
- Brand
- DIVALPROEX SODIUM
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Category
- Drug — Prescription Drug
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- 100 count bottle - Lot #C307859
- exp 09/2015
- 500 count bottle - Lot #C307859 and Lot# C307812
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Dr. Reddy's Laboratories, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · DIVALPROEX SODIUM
- ModerateDivalproex Sodium Delayed-Release Tablets Recalled Due to Presence of Foreign Tablets
FDA (Drugs) · 2026-07-29
- HighDivalproex Sodium 250 mg tablets recalled for failed dissolution specifications
FDA (Drugs) · 2024-04-03
- HighDivalproex Sodium Extended-Release Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2022-08-31
- HighFDA Recalls Divalproex Sodium Tablets for Failed Dissolution Specifications
FDA (Drugs) · 2022-08-03
- ModerateMajor Pharmaceuticals Recalls Divalproex Sodium Tablets Due to Humidity Exposure
FDA (Drugs) · 2019-08-07
Same manufacturer · Dr. Reddy's Laboratories, Inc.
See all →- ModerateVarenicline tablets recalled after an assay value fell below specification
FDA (Drugs) · 2025-12-17
- Moderate
- HighOmeprazole capsule bottle contained a foreign divalproex sodium tablet
FDA (Drugs) · 2025-07-23
- SevereLevetiracetam Injection Label Mismatch Nationwide Recall
FDA (Drugs) · 2025-04-23
- ModerateFDA Recalls JAVYGTOR Tablets Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-12-18
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paroxetine Hydrochloride Extended-Release Tablets for Dissolution Failure
FDA (Drugs) · 2026-10-07
- ModerateAjanta Pharma Recalls Ranolazine Tablets for Dissolution Failure
FDA (Drugs) · 2026-10-07
- ModerateMylan Recalls Mycophenolate Mofetil Injection Due to Dissolution Failures
FDA (Drugs) · 2026-09-09
- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
Similar recalls
- HighDr. Reddy's Recalls Divalproex Sodium Tablets for Dissolution Failure
FDA (Drugs) · 2019-02-27
- ModerateDr. Reddy's Recalls Divalproex Sodium Tablets Due to Humidity Exposure
FDA (Drugs) · 2019-04-24
- ModerateZydus Recalls Divalproex Sodium Tablets for Failed Dissolution Specifications
FDA (Drugs) · 2017-08-09
- HighDivalproex Sodium Extended-Release Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2022-08-31
- HighDivalproex Sodium 250 mg tablets recalled for failed dissolution specifications
FDA (Drugs) · 2024-04-03
- HighFDA Recalls Divalproex Sodium Tablets for Failed Dissolution Specifications
FDA (Drugs) · 2022-08-03